Login to Your Account



NEXT STEPS: MEETING WITH FDA, EMA

Amicus Therapeutics paves path to reviews with positive phase III Fabry data

By Michael Fitzhugh
Staff Writer

Thursday, August 21, 2014
Amicus Therapeutics Inc.'s shares (NASDAQ:FOLD) rocketed 20.4 percent Wednesday as the company delivered positive top-line data from a second phase III study of migalastat, its oral small-molecule chaperone for Fabry disease patients with a genetic mutation making them amenable to treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription